Navigation Links
Study Shows Sutro Biopharma's Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals
Date:5/19/2011

SAN FRANCISCO, May 19, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that a study published in the July issue of Biotechnology and Bioengineering demonstrates that the company's biochemical protein synthesis technology platform enables fast and high-yield protein synthesis and scale-up with straightforward downstream purification processes.

In the study, the fully bioactive cytokine human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was produced at linearly scalable levels from frozen extract of Sutro's E.coli-based open cell-free synthesis (OCFS) system. The disulfide-bonded biotherapeutic protein was produced at titers of 700 mg/L in 10 hours, demonstrating the potential of the company's technology for cGMP production.

"The study showed that Sutro's biochemical protein synthesis technology platform provides a robust, linearly-scalable system that allows the industrial production of disulfide-bonded proteins such as GM-CSF, and since the study was published, we have been able to double production efficiency per batch," said Christopher Murray, Ph.D., vice president of research at Sutro Biopharma and senior author of the publication. "The company's platform also enables the synthesis of proteins that contain site-specific non-natural amino acids as well as proteins that cannot be expressed using conventional technologies, allowing us to explore novel protein therapeutics that have been inaccessible, and even unimaginable, until now."

The authors extended and optimized the E. coli-based system that was developed by James R. Swartz, Sc.D., director and founder of Sutro Biopharma, to this OCFS system for high-level production of rhGM-CSF. The production capacity of the activated extract after freezing and storage at -40 degrees C and -80 degrees C was retained, even after multiple freeze-thaw cycles. The approach demonstrated robust protein production with more than 95 percent correctly folded multi-disulfide-bonded protein and 65 percent recovery.

The publication was also featured in Biotechnology and Bioengineering's Spotlight section of the same issue.

About Sutro Biopharma

Sutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology opens up opportunities to create protein therapeutics that cannot be produced using conventional methods. Sutro's technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once identified, the company can efficiently scale production to commercial levels. In addition to developing its own drug pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies.

Media Contacts:

David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4292
(347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Sutro Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. New study predicts risk of wetland habitat loss in southern United States
2. Greenhouse ocean study offers warning for future
3. Rigorous study confirms video game playing increases food intake in teens
4. Study reveals need for personalized approach in treatment of AML
5. Study finds therapies using induced pluripotent stem cells could encounter immune rejection problems
6. Oregon Farm to School bill would benefit health through job creation, study finds
7. Study shows evolutionary adaptations can be reversed, but rarely
8. MIT Study: conventional fossil fuels sometimes greener than biofuels
9. Clemson University institute to study vertical farming feasibility in Charleston, S.C.
10. Study: Pace of brain development still strong in late teens
11. WSU study expands time window for facial nerve rehabilitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology: